1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Drugs In Development, 2022, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 8, 3, 1, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 4 molecules, respectively.
Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Peanut Allergy - Overview
- Peanut Allergy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Peanut Allergy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Peanut Allergy - Companies Involved in Therapeutics Development
- Peanut Allergy - Drug Profiles
- Peanut Allergy - Dormant Projects
- Peanut Allergy - Discontinued Products
- Peanut Allergy - Product Development Milestones
- Featured News & Press Releases
- Jul 03, 2022: Aimmune Therapeutics to present new data for PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
- Jul 01, 2022: Allergy Therapeutics showcases allergy immunotherapy leadership at Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2022
- Jun 27, 2022: ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
- Jun 22, 2022: Intrommune announces expanded scope of phase 1 OMEGA study in adults with peanut allergy
- Jun 01, 2022: Intrommune Therapeutics names Nandini Murthy as head of regulatory
- May 16, 2022: Prota Therapeutics achieves 51 percent peanut allergy remission rate, first company to validate significant quality of life improvements compared with standard care
- May 11, 2022: Intrommune previews Phase II trial design for peanut allergy toothpaste
- Apr 25, 2022: Allergy Therapeutics shares positive data on VLP Peanut at the 2022 WAO-BSACI Conference
- Apr 06, 2022: INT301 continues to meet safety goals in phase 1 omega study in adults with peanut allergy while reaching phase 2 target maintenance dose
- Mar 04, 2022: Aravax opens IND for PVX108 Phase 2 trials and strengthens SAB
- Mar 01, 2022: Allergy Therapeutics shares positive new data at the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting
- Feb 16, 2022: Aimmune Therapeutics announces publication of pooled safety analysis of PALFORZIA treatment for up to 2 years in the Journal of Allergy and Clinical Immunology
- Feb 09, 2022: Prota Therapeutics achieves peanut allergy treatment milestone: groundbreaking clinical trial data demonstrates clinical remission of peanut allergy in paediatric patients
- Feb 08, 2022: Intrommune reports positive update from ongoing phase 1 study in peanut allergy
- Jan 26, 2022: Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Peanut Allergy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, 2022
- Peanut Allergy - Pipeline by ALK-Abello AS, 2022
- Peanut Allergy - Pipeline by Allakos Inc, 2022
- Peanut Allergy - Pipeline by Allergy Therapeutics Plc, 2022
- Peanut Allergy - Pipeline by Angany Inc, 2022
- Peanut Allergy - Pipeline by Aravax Pty Ltd, 2022
- Peanut Allergy - Pipeline by AstraZeneca Plc, 2022
- Peanut Allergy - Pipeline by BioLingus AG, 2022
- Peanut Allergy - Pipeline by BlueWillow Biologics Inc, 2022
- Peanut Allergy - Pipeline by Cambridge Allergy Ltd, 2022
- Peanut Allergy - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
- Peanut Allergy - Pipeline by DBV Technologies SA, 2022
- Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Peanut Allergy - Pipeline by IgGenix Inc, 2022
- Peanut Allergy - Pipeline by Inimmune Corp, 2022
- Peanut Allergy - Pipeline by InnoUp Farma SL, 2022
- Peanut Allergy - Pipeline by Intrommune Therapeutics Inc, 2022
- Peanut Allergy - Pipeline by Mabylon AG, 2022
- Peanut Allergy - Pipeline by Moonlight Therapeutics Inc, 2022
- Peanut Allergy - Pipeline by Novartis AG, 2022
- Peanut Allergy - Pipeline by Phlaxis, 2022
- Peanut Allergy - Pipeline by Prota Therapeutics Pty Ltd, 2022
- Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Peanut Allergy - Pipeline by Sementis Ltd, 2022
- Peanut Allergy - Pipeline by Ukko Inc, 2022
- Peanut Allergy - Pipeline by Vedanta Biosciences Inc, 2022
- Peanut Allergy - Pipeline by Virtici LLC, 2022
- Peanut Allergy - Dormant Projects, 2022
- Peanut Allergy - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Peanut Allergy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aimmune Therapeutics Inc
- ALK-Abello AS
- Allakos Inc
- Allergy Therapeutics Plc
- Angany Inc
- Aravax Pty Ltd
- AstraZeneca Plc
- BioLingus AG
- BlueWillow Biologics Inc
- Cambridge Allergy Ltd
- Cour Pharmaceuticals Development Co Inc
- DBV Technologies SA
- F. Hoffmann-La Roche Ltd
- IgGenix Inc
- Inimmune Corp
- InnoUp Farma SL
- Intrommune Therapeutics Inc
- Mabylon AG
- Moonlight Therapeutics Inc
- Novartis AG
- Phlaxis
- Prota Therapeutics Pty Ltd
- Regeneron Pharmaceuticals Inc
- Sementis Ltd
- Ukko Inc
- Vedanta Biosciences Inc
- Virtici LLC
